Investing in the artificial intelligence theme has been nothing short of a wild ride in 2026, especially when it comes to stocks that are not household names. Few stocks provide a better example of this dynamic than the semiconductor testing equipment company Aehr Test Systems (NASDAQ: AEHR).
Throughout the year, Aehr has moved from a market capitalization of less than $700 million to well over $3 billion. This has resulted in a year-to-date (YTD) return that exceeds 400%, making Aehr easily one of the best-performing stocks of 2026.
Aehr had already delivered a very impressive performance through July, up nearly 300% YTD. However, the stock has moved into a different stratosphere in August, with shares up more than 30% during the month. This comes despite AEHR dropping 25% from its August high, demonstrating the immense volatility that surrounds the stock.
Notably, repeated orders for Aehr’s AI chip testing systems, rather than hype, drive its ascendance, with two recent orders pushing shares to new heights.
Aehr Secures Millions in Orders for FOX-XP
Aehr has highlighted two new orders, one small and one large, but both are notable. First, the company says it has received an order from its lead silicon photonics customer for a FOX-XP system. FOX-XP is Aehr’s wafer-level burn-in (WBLI) machine, which puts semiconductor wafers under intense conditions to test for defects. The order is notable because it is from a silicon photonics customer, which is a high-growth area within the AI semiconductor industry. Experts expect silicon photonics to become increasingly important within AI networking due to its superior bandwidth compared to copper-based networking.
Thus, gaining silicon photonics customers signals Aehr’s ability to generate demand from this high-growth market. Furthermore, this is a repeat order, showing that the customer has found Aehr’s machines useful and is supporting production with additional orders. Still, the order is small at just one FOX-XP system.
Aehr’s second order announcement is far more significant. Aehr notes that it has also received a follow-on order from its lead wafer-level AI processor customer, which makes AI training and inference chips. The order, valued at $22 million, includes multiple FOX-XP machines and various types of ancillary equipment. At first glance, a $22 million order sounds relatively small, but Aehr is a relatively small company.
Investors should note that several months ago, Aehr said it had received a $41 million commitment, which marked a record order for the company. In turn, bringing in a new order that is just more than half the size of its largest ever is very significant. This is especially true when it comes to Aehr’s ability to meet its guidance.
Aehr’s Recent Orders Support Lofty Guidance Goals
Aehr released blockbuster guidance during its last earnings report, estimating that it would generate $130 million to $150 million in sales in its fiscal year 2027 (FY2027). (Note that Aehr’s fiscal reporting period is several quarters ahead of the calendar year period, with its FY2027 having begun in June.) Achieving these figures would represent explosive growth of approximately 160% to 200% year-over-year compared to its fiscal year 2026 sales of $50 million.
At the time of its last report, Aehr’s effective backlog of $100.6 million covered around 66% to 77% of its revenue guidance. With the new $22 million order expected to ship in the next six months, it should contribute directly to Aehr’s FY2027 revenue target. All else being equal, the figure would move Aehr’s effective backlog to $122.6 million.
Thus, the company’s effective backlog would account for approximately 82% to 94% of revenue guidance, substantially increasing the likelihood that it meets its target. Notably, to meet the midpoint of its guidance ($140 million), Aehr only needs to generate and deliver additional orders worth approximately $18.4 million.
With the company generating at least $22 million in orders in the first three months of FY2027, Aehr appears on track to meet its goal. Aehr says that its AI processor customers' “current production plans contemplate capacity beyond this order," suggesting they could send in more orders going forward.
Aehr Gains Sky-High Price Target as Valuation Bakes in Big-Time Growth
Aehr now trades at a forward price-to-sales (P/S) ratio of approximately 25x. This highly elevated figure demonstrates the huge amount of growth the market is baking into this stock going forward. However, it is significantly below Aehr’s peak forward P/S ratio near 45x.
Aehr carries a Buy rating with a price target of $136.67 and has recently received a lofty $175 price target from Jefferies. Jefferies recently initiated coverage on this name, and their target implies large upside going forward. However, if Aehr is to reach this target, the stock is unlikely to move in a straight line. Aehr can see single-day gains and drops of 20% or more, further showing the high-risk nature of this stock.
Investors interested in this name should monitor Aehr’s ability to convert its large backlog into actual revenue going forward, which requires strong production execution. Additionally, it will be important to see if Aehr expands its customer base into new areas of AI chips. Order announcements around memory chip or central processing unit (CPU) customers would be particularly notable, as they are also high-growth AI infrastructure segments.
The article "Aehr Test Systems Soars Again on Latest Orders, Jefferies Eyes Big-Time Upside Ahead" first appeared on MarketBeat.
